DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1416 Bray PG, Ward SA, O’Neill PM. Quinolines and artemisinin:
Chemistry, biology and history. Curr Top Microbiol Immunol,
2005, 295:3–38.
Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised
antimalarial treatment with six-dose artemetherlumefantrine:
Pharmacokinetic and dosage-related findings
from a clinical trial in Uganda. Malar J, 2006, 5:59.
Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in
long-term travelers. JAMA, 2006, 296:2234–2244.
Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia.
Treatment issues. Drug Saf, 1996, 14:394–405.
Cooper RA, Ferdig MT, Su XZ, et al. Alternative mutations at
position 76 of the vacuolar transmembrane protein PfCRT are
associated with chloroquine resistance and unique stereospecific
quinine and quinidine responses in Plasmodium falciparum.
Mol Pharmacol, 2002, 61:35–42.
Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi
malaria in humans is widely distributed and potentially life
threatening. Clin Infect Dis, 2008, 46:165–171.
Dahl EL, Rosenthal PJ. Apicoplast translation, transcription and
genome replication: Targets for antimalarial antibiotics. Trends
Parasitol, 2008, 24:279–284.
Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination
therapies for uncomplicated malaria. Med J Aust,
2005, 182:181–185.
de Beer TA, Wells GA, Burger PB, et al. Antimalarial drug discovery:
In silico structural biology and rational drug design.
Infect Disord Drug Targets, 2009, 9:304–318.
Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety
of artemisinins during pregnancy: A pressing question. Malar J,
2007, 6:15.
Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in
Plasmodium falciparum malaria. N Engl J Med, 2009,
361:455–467.
Druilhe P, Daubersies P, Patarapotikul J, et al. A primary malarial
infection is composed of a very wide range of genetically
diverse but related parasites. J Clin Invest, 1998, 101:
2008–2016.
Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism
of chloroquine. Focus on recent advancements. Clin
Pharmacokinet, 1996, 31:257–274.
Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to
antimalarial drug-resistance. Acta Trop, 2005, 94:181–190.
Eastman RT, Fidock DA. Artemisinin-based combination therapies:
A vital tool in efforts to eliminate malaria. Nat Rev
Microbiol, 2009, 7:864–874.
Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity.
Clinical and pathologic perspective. Am J Med,
1987, 82:447–455.
Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum
digestive vacuole transmembrane protein PfCRT and
evidence for their role in chloroquine resistance. Mol Cell,
2000, 6:861–871.
Fidock DA, Wellems TE. Transformation with human dihydrofolate
reductase renders malaria parasites insensitive to WR99210
but does not affect the intrinsic activity of proguanil. Proc Natl
Acad Sci USA, 1997, 94:10931–10936.
Fitch, CD. Choloroquine resistance in malaria: A deficiency of
chloroquine binding. Proc Natl Acad Sci USA, 1969,
64:1181–1187.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Fivelman QL, Adagu IS, Warhurst DC. Modified fixed-ratio
isobologram method for studying in vitro interactions between
atovaquone and proguanil or dihydroartemisinin against drugresistant
strains of Plasmodium falciparum. Antimicrob Agents
Chemother, 2004, 48:4097–4102.
Freedman DO. Clinical practice. Malaria prevention in shortterm
travelers. N Engl J Med, 2008, 359:603–612.
Gardiner DL, Skinner-Adams TS, Brown CL, et al. Plasmodium
falciparum: New molecular targets with potential for antimalarial
drug development. Expert Rev Anti Infect Ther, 2009,
7:1087–1098.
Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia
in HIV-infected children following treatment with artesunate
plus amodiaquine for uncomplicated malaria in Uganda.
Clin Infect Dis, 2008, 46:985–991.
German PI, Aweeka FT. Clinical pharmacology of artemisinin-based
combination therapies. Clin Pharmacokinet, 2008, 47:91–102.
Ginsburg H, Golenser J. Glutathione is involved in the antimalarial
action of chloroquine and its modulation affects drug sensitivity
of human and murine species of Plasmodium. Redox
Rep, 2003, 8:276–279.
Goldberg DE. Hemoglobin degradation. Curr Top Microbiol
Immunol, 2005, 295:275–291.
Golenser J, Waknine JH, Krugliak M, et al. Current perspectives
on the mechanism of action of artemisinins. Int J Parasitol,
2006, 36:1427–1441.
Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites
to antifolates. Pharmacol Rev, 2005, 57:117–145.
Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria
in the United States: A systematic review. JAMA, 2007, 297:
2264–2277.
Harrington WE, Mutabingwa TK, Muehlenbachs A, et al.
Competitive facilitation of drug-resistant Plasmodium falciparum
malaria parasites in pregnant women who receive preventive
treatment. Proc Natl Acad Sci USA, 2009, 106:
9027–9032.
Hayton K, Su XZ. Drug resistance and genetic mapping in
Plasmodium falciparum. Curr Genet, 2008, 54:223–239.
Hellgren U, Berggren-Palme I, Bergqvist Y, Jerling M.
Enantioselective pharmacokinetics of mefloquine during longterm
intake of the prophylactic dose. Br J Clin Pharmacol,
1997, 44:119–124.
Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic
acid antagonists during pregnancy and the risk of birth defects.
N Engl J Med, 2000, 343:1608–1614.
Hill DR, Baird JK, Parise ME, et al. Primaquine: Report from
CDC expert meeting on malaria chemoprophylaxis I. Am J
Trop Med Hyg, 2006, 75:402–415.
Hyde JE. Targeting purine and pyrimidine metabolism in human
apicomplexan parasites. Curr Drug Targets, 2007, 8:31–47.
Kain KC, Jong EC. Malaria prevention. In: Malaria Prevention
(Jong E.C., McMullen R., eds.), Saunders, Philadelphia, 2003,
52–74.
Kamchonwongpaisan S, Quarrell R, Charoensetakul N, et al.
Inhibitors of multiple mutants of Plasmodium falciparum
dihydrofolate reductase and their antimalarial activities. J Med
Chem, 2004, 47:673–680.
Kessl JJ, Meshnick SR, Trumpower BL. Modeling the molecular
basis of atovaquone resistance in parasites and pathogenic
fungi. Trends Parasitol, 2007, 23:494–501.